 SARASOTA, Fla. and NOVATO, Calif., May 19, 2021 GLOBE NEWSWIRE -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced that they have received clearance from Health Canada to begin enrolling the Phase 12 study of GTX-102 in pediatric patients with Angelman syndrome in Canada. The first patient in Canada is expected to be enrolled in the early second half of 2021, with clinical data from some patients in the study expected before the end of 2021. 